Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

16.10 -0.20 (-1.23%)
Streaming Delayed Price Updated: 1:08 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone ↗
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday. 
Via Stocktwits
News headline image
Why Hims & Hers Health (HIMS) Stock Is Trading Up Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market. 
Via StockStory
News headline image
Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone ↗
The company is making a move into a highly anticipated area and partnering with a privately held pharmaceutical company. 
Via Investor's Business Daily
Topics ETFs
News headline image
Hims & Hers Bets On Hormonal Health To Revive Investor Confidence ↗
Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows. 
Via Benzinga
News headline image
Hims & Hers To Launch Low Testosterone Treatments for Men As Weight-Loss Drug Sales Slow ↗
The telehealth company is expanding into hormonal health with plans to eventually add therapies for women in perimenopause and menopause. 
Via Stocktwits
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Hims & Hers Health (HIMS) Stock Is Up Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst... 
Via StockStory
Topics ETFs Economy
News headline image
4 Top Stocks to Buy in September ↗
Here are four stocks to buy now that could offer investors upside in both the short and long term. 
Via The Motley Fool
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank? ↗
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
News headline image
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire ↗
Hims & Hers, which boasts a $9.7 billion market cap, is up 170% over the past year, though it's pulled back nearly 25% this past month. 
Via Benzinga
News headline image
Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers ↗
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses. 
Via Benzinga
Topics ETFs
News headline image
Healthcare Technology Stocks Q2 Highlights: Hims & Hers Health (NYSE:HIMS)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at healthcare technology stocks, starting... 
Via StockStory
News headline image
Defiance Rolls Out Leveraged ETFs Targeting AMD, Supermicro, Palantir, Hims & Robinhood ↗
Defiance ETFs introduces 5 new leveraged ETFs providing magnified exposure to popular tech, healthcare, and retail stocks, with a mix of growth and income. 
Via Benzinga
Topics ETFs
News headline image
Got $5,000? 3 Tech Stocks to Buy and Hold for the Long Term ↗
As the value of your investment portfolio rises over time, you will also be better equipped for retirement. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets ↗
The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme. 
Via MarketBeat
News headline image
Why Hims & Hers Health (HIMS) Stock Is Falling Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from... 
Via StockStory
Topics ETFs Economy Lawsuit
News headline image
What's Going On With Hims & Hers Shares Today? ↗
Hims & Hers Health shares are trading lower Tuesday after GoodRx announces a collaboration with Novo Nordisk. 
Via Benzinga
News headline image
Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4 ↗
A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Autonomous Vehicles Hit an Inflection Point; GPT-5 Is Here ↗
Motley Fool Money checks in on some stock market news. 
Via The Motley Fool
Topics Economy
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets ↗
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S. 
Via Benzinga
News headline image
CoreWeave, Applied Materials And Hims & Hers Are Among Top 10 Large Cap Losers Last Week (August 11-August 15): Are The Others In Your Portfolio? ↗
Ten large-cap stocks, including CRWV, COHR & AMZN, were the worst performers last week. Weak results, downgrades, and FTC probe may be the reasons. 
Via Benzinga
News headline image
Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces ↗
Via Benzinga
News headline image
1 Stock Under $50 with Solid Fundamentals and 2 We Ignore
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
1 Mid-Cap Stock with Competitive Advantages and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
Topics Retirement
News headline image
HIMS Q2 Deep Dive: International Expansion and Product Shifts Define Next Growth Phase
Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.